retatrutide clinical trials safety data Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial retatrutide safety profile clinical trials

The study excluded individuals with type 2 diabetes, despite this population frequently presenting with NAFLD, so it remains uncertain whether these safety outcomes would be applicable to them

If weight loss plateaus or is less than expected after 3-4 months at the maintenance dose, clinicians should reassess adherence, evaluate for medication interactions, and reinforce lifestyle modifications

It remains an investigational compound available for laboratory research only

Reports suggest a surge in off-label use among non-diabetic individuals driven by online hype

Investigators are studying whether the combined triple-agonist effect on appetite, energy expenditure, and hepatic lipid handling translates to reductions in liver fat content

Trimi's published materials describe its program as FSA and HSA eligible